Showing results (571-580 of 1,188) with videos related to

Sort By:
Pageof 119
Cancer|June 5, 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinosideGuillermo Garcia-Manero, Moshe Talpaz, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controlsHagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemiaPaolo Strati, Naval Daver, Farhad Ravandi, et al.
Leukemia & Lymphoma|August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experienceOhad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2024
Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating AgentsGuillermo Garcia-Manero, Rayna K Matsuno, Ali McBride, et al.
Cancer Chemotherapy and Pharmacology|September 19, 2003
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemiaApostolia M Tsimberidou, Elihu Estey, Jorge E Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemiaFrancis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
Nature Communications|November 13, 2024
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trialJuan Jose Rodriguez-Sevilla, Vera Adema, Kelly S Chien, et al.
Cancer|April 4, 2006
Thalidomide therapy for myelofibrosis with myeloid metaplasiaDeborah A Thomas, Francis J Giles, Maher Albitar, et al.
Pageof 119